View : 24 Download: 0

CLINICAL IMPACT BY 24 MONTHS ACCORDING TO BCR/ABL1 TRANSCRIPT LEVEL AT 3 AND 6 MONTHS IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH RADOTINIB 300MG BID OR IMATINIB

Title
CLINICAL IMPACT BY 24 MONTHS ACCORDING TO BCR/ABL1 TRANSCRIPT LEVEL AT 3 AND 6 MONTHS IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH RADOTINIB 300MG BID OR IMATINIB
Authors
Do, Y. R.Kwak, J. -Y.Kim, H.Kim, J. -A.Kim, H. J.Park, J. S.Chung, J. S.Shin, H. -J.Kim, S. -H.Kim, D. -Y.Bunworasate, U.Choi, C. W.Comia, N. S.Zang, D. Y.Oh, S. J.Jootar, S.Reksodiputro, A. H.Lee, W. S.Mun, Y. -C.Kong, J. H.Caguioa, P. B.Park, J.Jung, C. W.Kim, D. -W.
Ewha Authors
문영철
SCOPUS Author ID
문영철scopus
Issue Date
2017
Journal Title
HAEMATOLOGICA
ISSN
0390-6078JCR Link
Citation
vol. 102, pp. 441 - 441
Publisher
FERRATA STORTI FOUNDATION
Indexed
SCI; SCIE; SCOPUS WOS
Appears in Collections:
의학전문대학원 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE